#+HashtagPLUS
In

Menu

Post image 1
Post image 2
Post image 3
Post image 4
Post image 5
Post image 6
Post image 7
Post image 8
Post image 9
Post image 10
Post image 11
Post image 12
Post image 13
Post image 14
Post image 15
Post image 16
Post image 17
Post image 18
Post image 19
Post image 20
Post image 21
Post image 22
Post image 23
Post image 24
Post image 25
Post image 26
Post image 27
Post image 28
Post image 29
Post image 30
Post image 31
Post image 32
Post image 33
Post image 34
1 / 34
0

Daiichi Sankyo bets on new cancer drugs to fuel future growth

The Japan Times·Eru Ishikawa·21 days ago
#nmTd0yyU
#daiichisankyo#health#pharmaceuticals#medicine#patents#daiichi
Reading 0:00
15s threshold

"The next five years are critical in defining Daiichi Sankyo’s future,” CEO Hiroyuki Okuzawa said Tuesday. | 418265747 Daiichi Sankyo is betting on a new wave of antibody-drug conjugates to reduce its reliance on Enhertu, as the Japanese drugmaker pushes to expand its oncology business ahead of the blockbuster cancer treatment’s patent expiry. "The next five years are critical in defining Daiichi Sankyo’s future,” CEO Hiroyuki Okuzawa said in an interview Tuesday. "We have no intention of making Daiichi Sankyo a company that just happened to hit with ADC and ended there.” The company aims to more than double oncology revenue to above ¥2.3 trillion ($14.6 billion) by 2030 and become one of the world’s top five oncology players by 2035. The targets, outlined in a midterm plan released Monday, come as investors assess growth prospects beyond Enhertu, which generated about ¥700 billion in sales in fiscal 2025 and has become its primary earnings driver.…

Continue reading — create a free account

Join HashtagPLUS to read full articles, follow hashtags, vote, and join the conversation.

Create free accountLog in
Read More